



Clinical trial results:

A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2016-002222-37 |
| Trial protocol | DK |
| Global end of trial date | 08 February 2018 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 12 October 2019 |
| First version publication date | 12 October 2019 |

Trial information

Trial identification

| | |
|-----------------------|------|
| Sponsor protocol code | 1626 |
|-----------------------|------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Herlev Hospital |
| Sponsor organisation address | Herlev Ringvej 75, Herlev, Denmark, 2730 |
| Public contact | Dorte Nielsen, Oncology dept. Herlev og Gentofte Hospital, +45 38682344, dorte.nielsen.01@regionh.dk |
| Scientific contact | Dorte Nielsen, Oncology dept. Herlev og Gentofte Hospital, +45 38682344, dorte.nielsen.01@regionh.dk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 08 February 2018 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 08 February 2018 |
| Global end of trial reached? | Yes |
| Global end of trial date | 08 February 2018 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

Overall survival between the two groups

Protection of trial subjects:

Eligibility criteria, no additional specific measures

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------------|
| Actual start date of recruitment | 02 September 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Denmark: 7 |
| Worldwide total number of subjects | 7 |
| EEA total number of subjects | 7 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 4 |
| From 65 to 84 years | 3 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Recruitment was open from september 2016 to october 2017, single center trial at Herlev University Hospital

Pre-assignment

Screening details:

not applicable

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|-------------|
| Arm title | Regorafenib |
|------------------|-------------|

Arm description:

Experimental arm

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Regorafenib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

160 mg daily for 3 weeks in a 4-weeks cycle

| | |
|------------------|----------|
| Arm title | Standard |
|------------------|----------|

Arm description: -

| | |
|--|---------------------------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Irinotecan |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

180 mg/m² every 2 weeks

| | |
|--|---------------------------------------|
| Investigational medicinal product name | Bevacizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

5 mg/kg every 2 weeks

| | |
|--|---------------------------------------|
| Investigational medicinal product name | Panitumumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

6 mg/kg every 2 weeks

| Number of subjects in period 1 | Regorafenib | Standard |
|---------------------------------------|-------------|----------|
| Started | 3 | 4 |
| Completed | 3 | 4 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|-------------|
| Reporting group title | Regorafenib |
| Reporting group description: | |
| Experimental arm | |
| Reporting group title | Standard |
| Reporting group description: - | |

| Reporting group values | Regorafenib | Standard | Total |
|--|-------------|----------|-------|
| Number of subjects | 3 | 4 | 7 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous | | | |
| Units: years | | | |
| median | 67 | 59.5 | |
| full range (min-max) | 56 to 68 | 58 to 70 | - |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 1 | 2 | 3 |
| Male | 2 | 2 | 4 |

End points

End points reporting groups

| | |
|--------------------------------|-------------|
| Reporting group title | Regorafenib |
| Reporting group description: | |
| Experimental arm | |
| Reporting group title | Standard |
| Reporting group description: - | |

Primary: OS

| | |
|------------------------|-------------------|
| End point title | OS ^[1] |
| End point description: | |

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

From time of randomisation to death or last FU

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analyses not performed due to low number of patient

| End point values | Regorafenib | Standard | | |
|-------------------------------|------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 4 | | |
| Units: year | | | | |
| median (full range (min-max)) | 5.6 (3.1 to 7.1) | 7.1 (2.3 to 8.9) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment start to 30 days after last treatment

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|-----------|
| Dictionary name | NCI-CTCAE |
|-----------------|-----------|

| | |
|--------------------|-----|
| Dictionary version | 4.0 |
|--------------------|-----|

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Regorafenib |
|-----------------------|-------------|

Reporting group description:

Experimental arm

| | |
|-----------------------|----------|
| Reporting group title | Standard |
|-----------------------|----------|

Reporting group description: -

| Serious adverse events | Regorafenib | Standard | |
|--|----------------|----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 1 / 4 (25.00%) | |
| number of deaths (all causes) | 2 | 2 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| General disorders and administration site conditions | | | |
| Syncope | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Paresis OE dex | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Regorafenib | Standard | |
|---|-----------------|-----------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 3 (100.00%) | 4 / 4 (100.00%) | |
| Investigations | | | |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | |
| occurrences (all) | 0 | 1 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | |
| occurrences (all) | 0 | 2 | |
| Cardiac disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | |
| occurrences (all) | 0 | 1 | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 0 / 4 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 1 / 4 (25.00%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| Diarrhea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 3 / 4 (75.00%) | |
| occurrences (all) | 1 | 3 | |
| Nausea | | | |
| subjects affected / exposed | 1 / 3 (33.33%) | 3 / 4 (75.00%) | |
| occurrences (all) | 1 | 3 | |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 4 / 4 (100.00%) | |
| occurrences (all) | 0 | 4 | |
| Skin and subcutaneous tissue disorders | | | |
| Rash | | | |
| subjects affected / exposed | 0 / 3 (0.00%) | 2 / 4 (50.00%) | |
| occurrences (all) | 0 | 2 | |
| Palmar-plantar erythrodysaesthesia syndrome | | | |

| | | | |
|--|---------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 0 / 4 (0.00%) 0 | |
| Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all) | 1 / 3 (33.33%) 1 | 2 / 4 (50.00%) 2 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

| |
|------------------------------|
| recruitment goal not reached |
|------------------------------|

Notes: